Acute thrombocytopenia induced by trastuzumab due to complement reaction: A case report

Guoping Chen; Guoping Chen; Jianghua Ou; Jun Liu; Haoran Liao; Linwei Ding; Pingming Fan; Guankui Du; Guankui Du; Guankui Du; Guankui Du; Guankui Du

doi:10.3389/fmed.2022.1037493

Frontiers in Medicine (Dec 2022)

Acute thrombocytopenia induced by trastuzumab due to complement reaction: A case report

Guoping Chen,
Guoping Chen,
Jianghua Ou,
Jun Liu,
Haoran Liao,
Linwei Ding,
Pingming Fan,
Guankui Du,
Guankui Du,
Guankui Du,
Guankui Du,
Guankui Du

Affiliations

Guoping Chen: Department of Breast Surgery, Affiliated Tumor Hospital of Xinjiang Medical University, Ürümqi, China
Guoping Chen: Department of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, China
Jianghua Ou: Department of Breast Surgery, Affiliated Tumor Hospital of Xinjiang Medical University, Ürümqi, China
Jun Liu: Department of Immunology, Hainan Medical University, Haikou, China
Haoran Liao: Department of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, China
Linwei Ding: Department of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, China
Pingming Fan: Department of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, China
Guankui Du: Department of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, China
Guankui Du: Department of Immunology, Hainan Medical University, Haikou, China
Guankui Du: Key Laboratory of Molecular Biology, Hainan Medical University, Haikou, China
Guankui Du: Department of Biochemistry and Molecular Biology, Hainan Medical University, Haikou, China
Guankui Du: Biotechnology and Biochemistry Laboratory, Hainan Medical University, Haikou, China

DOI: https://doi.org/10.3389/fmed.2022.1037493
Journal volume & issue: Vol. 9

Abstract

Read online

BackgroundThe usual treatment option for HER2 breast cancer is targeted therapy with trastuzumab. The common adverse effects of trastuzumab treatment are thrombocytopenia, however, acute thrombocytopenia is rare and its mechanism is still largely unknown.Case presentationWe reported a patient who presented with acute thrombocytopenia on two consecutive occasions, and the predisposing factor was identified on the second occasion because of trastuzumab-only treatment. Routine blood results showed a dramatic increase in white blood cell count and neutrophil count after both trastuzumab treatments. Moreover, the complement reaction results suggested that the dramatic thrombocytopenia was probably due to platelet destruction after complement activation.ConclusionThis case suggests that it would be useful to perform a platelet complement reaction test before trastuzumab treatment in patients with HER2 breast cancer.

Published in Frontiers in Medicine

ISSN: 2296-858X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Medicine (General)
Website: http://www.frontiersin.org/journals/medicine

About the journal

Abstract

Keywords